Cancer of the Esophagus Clinical Trial
Official title:
Evaluating the Feasibility and Safety of Using Nasal High Flow Oxygen for Five Days Postoperatively to Reduce Respiratory Complications After Oesophagectomy for Cancer
The use of nasal high flow in patients undergoing oesophagectomy is a novel technique that has not been previously studied. Nasal high flow will be delivered postoperatively to patients undergoing oesophagectomy in a tertiary cancer referral centre. This single-centre cohort study will evaluate the safety of using nasal high flow in oesophagectomy patients. Physiological parameters, adverse events and clinical outcome will be recorded in consecutive patients undergoing oesophagogastric surgery. This study will challenge the hypothesis that the use of nasal high-flow will lower the rates of breathing complications such as pneumonia thereby reducing the demands on intensive care, shortening hospital stay and improving patient quality of life. The results will inform the design of a larger multicentre clinical trial comparing nasal high flow to conventional methods by facilitating sample size calculation.
Respiratory complications including pneumonia, pleural effusion, adult respiratory distress syndrome and pulmonary embolism will be recorded. The primary endpoint will be the rate of postoperative respiratory complications within 30 days of oesophagectomy. Technical complications related to nasal high flow administration will be recorded and reasons for discontinuing nasal high flow documented. Other outcome including mortality, hospital stay, surgical complications and respiratory complications within 90 days of surgery will be considered as secondary endpoints. These data will assess the feasibility and safety of using nasal high flow in patients undergoing oesophagectomy. The rate of respiratory complications will be determined in a cohort of consecutive surgical patients together with other measures of outcome to form the basis of a series worthy of reporting. This may help gain insight into whether using nasal high flow could benefit patients, and whether further research to compare nasal high flow to conventional respiratory support would be of value. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00716157 -
Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation
|
N/A | |
| Terminated |
NCT03108885 -
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
|
||
| Recruiting |
NCT04046575 -
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT00821912 -
TaxXel: Taxotere and Xeloda in Esophageal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02642809 -
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
|
Phase 1 | |
| Withdrawn |
NCT02843750 -
Study of Inspiratory Muscle Training for Patients Undergoing Esophageal Surgery
|
N/A | |
| Completed |
NCT00318903 -
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
|
Phase 2 | |
| Completed |
NCT05688761 -
Nordic Gastric and Esophageal Tumor Study
|
||
| Active, not recruiting |
NCT02415101 -
Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer
|
N/A | |
| Completed |
NCT00578071 -
Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01183559 -
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
|
Phase 1 | |
| Recruiting |
NCT02530983 -
Mayo Clinic Upper Digestive Disease Survey
|
||
| Active, not recruiting |
NCT03482791 -
Proton Beam Therapy in the Treatment of Esophageal Cancer
|
N/A |